AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Clinical trials for AMYOTROPHIC LATERAL SCLEROSIS (ALS) explained in plain language.
Never miss a new study
Get alerted when new AMYOTROPHIC LATERAL SCLEROSIS (ALS) trials appear
Sign up with your email to follow new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
First human test of new ALS injection begins
Disease control OngoingThis is an early safety study testing a single spinal injection of an experimental drug called RJK002 in 9 people with ALS. The main goal is to see if the injection is safe and to find the right dose for future studies. Researchers will also track changes in patients' daily funct…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE1 • Sponsor: RJK Biopharma Ltd • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for ALS patients: experimental drug trial seeks to slow deadly disease
Disease control ENROLLING_BY_INVITATIONThis clinical trial is testing whether an experimental drug called NUZ-001 can slow down ALS progression and help patients maintain physical function longer. The study will involve 160 people with ALS who will receive either the active drug or a placebo. Researchers will measure …
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for ALS patients: experimental drug aims to slow deadly disease
Disease control OngoingThis study is testing whether a new oral drug called Usnoflast can slow the progression of ALS (Lou Gehrig's disease). It involves 240 adults with early-stage ALS who will take either the drug or a placebo for 36 weeks, followed by an optional 16-week period where everyone gets t…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Race against time: new drug aims to slow devastating ALS
Disease control OngoingThis study is testing whether an experimental drug called VHB937 can slow the progression of early-stage ALS (Lou Gehrig's disease). It will involve 251 adults who have had ALS symptoms for less than two years. Participants will receive either the drug or a placebo for 40 weeks, …
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC
-
Robotic glove tested to help ALS patients regain hand control
Symptom relief ENROLLING_BY_INVITATIONThis small pilot study is testing whether using a special robotic glove can help improve hand function and quality of life for people with Amyotrophic Lateral Sclerosis (ALS). Five participants with ALS will use the glove daily for eight weeks to see if it helps with grip strengt…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: NA • Sponsor: Nova Southeastern University • Aim: Symptom relief
Last updated Apr 04, 2026 00:20 UTC